Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation

Name: Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation
Published: 2010
License: Public Domain

Barbara Ann Karmanos Cancer Institute · 2010

ClinicalTrials.gov · Datasets · License: Public Domain · 2010

Open Source ↗

leukemia lymphoma

chronic myeloproliferative disorders, graft versus host disease, leukemia, lymphoma, lymphoproliferative disorder, multiple myeloma and plasma cell neoplasm, myelodysplastic syndromes, myelodysplastic/myeloproliferative neoplasms, accelerated phase chronic myelogenous leukemia, adult acute lymphoblastic leukemia in remission, adult acute myeloid leukemia in remission, adult acute myeloid leukemia with 11q23 (mll) abnormalities

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 831008
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.